Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised Phase II Study to Assess the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schedules (rAd26-rAd5, rAd26-rAd26, rAd26-ChAdOx1 and rAd26-mRNA-1273).

NCT05027672 is registered in ClinicalTrials.gov with Ministerio de Salud de Ciudad Autónoma de Buenos Aires as lead sponsor.

NCT NCT05027672
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05027672 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised Phase II Study to Assess the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schedules (rAd26-rAd5, rAd26-rAd26, rAd26-ChAdOx1 and rAd26-mRNA-1273).
Lead sponsor
Ministerio de Salud de Ciudad Autónoma de Buenos Aires
Phase
Phase 2
Overall status
Unknown status
Start date
July 30, 2021
Completion date
September 6, 2021
Enrollment
348 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 vaccines